Categories
Archives
- 2026
- 2025
- 2024
- 2023
Dec
03
Bridging Strategy and Innovation: Leadership in Action through the AES BRIDGE Program
Nov
04
Elevating the lives of people impacted by thymidine kinase 2 deficiency (TK2d)
Nov
03
U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Oct
31
Redefining Hidradenitis Suppurativa (HS) Care Through Community and Collaboration
Oct
31
BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years
Oct
27
Generalized myasthenia gravis management with shared decision-making
Oct
25
BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
Oct
23
Multidisciplinary Collaboration as the Future of Patient-Centered Care
Oct
14
Innovative Collaborations: Enhancing Epilepsy Care through UCB and Morehouse's Community-Based Approach